The latest regulatory salvo from the Trump administration on Medicare Part D and the Democratic takeover of the House of Representatives has the pharmaceutical industry scrambling to fight a multifront war to defend market-based pricing in the United States.
Chief editor, Rob Wright, discusses some forward-looking sessions from the annual CNS Summit, along with what to expect in Life Science Leader’s annual outlook issue.
ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.
The fate of your business rests largely on the willingness of individuals to choose to invest their best discretionary effort in your company’s cause — to dig deep for innovative ideas, to imagine solutions outside any box, to perceive subtle shifts and faint signals.
See the answer from Anu Hans, VP of strategic initiatives at Janssen Supply Chain.
Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.
Helen Torley, president and CEO of Halozyme Therapeutics, discusses hyaluronan and the role it plays in development of ENHANZE, PEGPH20 along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).
